Brokerages Set LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target at $94.57

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given an average rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $94.57.

Several analysts recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research upped their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

Institutional Trading of LeMaitre Vascular

Large investors have recently made changes to their positions in the company. NBC Securities Inc. lifted its stake in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. USA Financial Formulas acquired a new stake in LeMaitre Vascular in the third quarter valued at about $60,000. nVerses Capital LLC grew its position in LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC raised its stake in LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares in the last quarter. Finally, Van ECK Associates Corp bought a new position in shares of LeMaitre Vascular in the second quarter worth about $75,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Down 1.3 %

NASDAQ:LMAT opened at $92.84 on Monday. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 50.73, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. LeMaitre Vascular has a twelve month low of $52.88 and a twelve month high of $109.58. The stock’s 50 day moving average price is $97.93 and its two-hundred day moving average price is $90.59.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter last year, the firm posted $0.33 EPS. The company’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s payout ratio is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.